Pfizer Inc is investing more than $2.5 billion at its drug making plants in Belgium and Ireland, gearing up to launch new products it hopes can replace lost revenue as patents expire and COVID-19 vaccine sales decline.
The new US study will include up to 1,420 volunteers ages 18 to 55 to test the updated Omicron-based shots for use as a booster or for primary vaccinations. Researchers will examine the tweaked vaccine’s safety and how it revs up the immune system...
Eleven pharma companies led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing sector since 2018, according to a Reuters analysis, in a drive to better control production of the world’s priciest medicines.
South Africa’s Biovac Institute will start local production of Sanofi’s Hexaxim vaccine next year and Pfizer’s anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.
Pfizer and BioNTech said they have not fully reviewed the complaint, but expressed surprise over the litigation.
Albert Bourla said on Monday that he started taking Pfizer’s Paxlovid pill treatment and is isolating while he recovers.
In matters of human affairs, there is little stranger than our tendency to draw fine distinctions of style and status where none are needed. We do it with hats, with indie rock groups, with preschool programmes and, now, with vaccines.
Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalisations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial.
The health authorities said the body's immune system recognises the foreign organism and produces antibodies to fight it.